Cerevel Therapeutics (NASDAQ:CERE) Hits New 52-Week High at $43.61

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $43.61 and last traded at $43.57, with a volume of 1204585 shares trading hands. The stock had previously closed at $42.90.

Cerevel Therapeutics Price Performance

The firm has a 50 day moving average of $41.23 and a 200-day moving average of $41.78. The company has a market cap of $7.91 billion, a P/E ratio of -15.93 and a beta of 1.40. The company has a current ratio of 10.22, a quick ratio of 10.22 and a debt-to-equity ratio of 0.60.

Cerevel Therapeutics (NASDAQ:CERE) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.12). On average, equities research analysts predict that Cerevel Therapeutics Holdings, Inc. will post -2.59 EPS for the current year.

Insider Buying and Selling at Cerevel Therapeutics

In other Cerevel Therapeutics news, Director N Anthony Coles sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $41.18, for a total transaction of $1,029,500.00. Following the completion of the transaction, the director now owns 25,928 shares in the company, valued at approximately $1,067,715.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Cerevel Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its holdings in shares of Cerevel Therapeutics by 508.8% in the 2nd quarter. SG Americas Securities LLC now owns 29,424 shares of the biotechnology company’s stock worth $1,203,000 after purchasing an additional 24,591 shares during the period. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Cerevel Therapeutics in the 2nd quarter worth approximately $127,000. California State Teachers Retirement System boosted its holdings in shares of Cerevel Therapeutics by 63.9% in the 1st quarter. California State Teachers Retirement System now owns 122,437 shares of the biotechnology company’s stock worth $5,175,000 after purchasing an additional 47,747 shares during the period. Black Maple Capital Management LP purchased a new position in shares of Cerevel Therapeutics in the 1st quarter worth approximately $664,000. Finally, Blackstone Inc. boosted its holdings in shares of Cerevel Therapeutics by 142.0% in the 1st quarter. Blackstone Inc. now owns 35,196 shares of the biotechnology company’s stock worth $1,488,000 after purchasing an additional 20,651 shares during the period. Hedge funds and other institutional investors own 87.73% of the company’s stock.

Cerevel Therapeutics Company Profile

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.